REG - Nanoco Group PLC - Receives TSB Grant for Bio-imaging <Origin Href="QuoteRef">NANON.L</Origin>

NanocoAnnouncement

06/09/2014 02:04

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20140609:nRSI1627Ja


RNS Number : 1627J
Nanoco Group PLC
09 June 2014 
 
 For immediate release  9 June 2014  
 
 
NANOCO GROUP PLC 
 
("Nanoco" or "the Company") 
 
Receives Technology Strategy Board Grant for Bio-imaging 
 
Nanoco Group plc (AIM: NANO), a world leader in the development and
manufacture of cadmium-free quantum dots and other nanomaterials, announces
that it has been awarded a further £308,000 grant to support its research at
University College London (UCL) into the use of cadmium-free quantum dots in
the in-vivo imaging of cancer. 
 
The grant has been awarded by the Technology Strategy Board (TSB), the UK's
innovation agency, under its Biomedical Catalyst funding programme. UCL will
also receive a TSB grant under the Biomedical Catalyst programme to support
the project. 
 
Nanoco and UCL began joint research work in 2011 in which the fluorescence of
Nanoco quantum dots is being used to pinpoint malignant lymph nodes to guide
surgeons in the removal of cancerous tissue. Other materials have already been
used in this way in clinical practice but Nanoco quantum dots offer the major
advantage of fluorescing for a longer period of time, giving surgeons a
greater opportunity to remove cancer cells. 
 
The TSB funding announced today will be used to support the next stage of the
joint research programme. 
 
Michael Edelman, Nanoco's Chief Executive Officer, said: "We're delighted to
receive this grant award from the Technology Strategy Board for our exciting
work with University College London in cancer imaging. Our work to date shows
that the sustained fluorescence achievable with Nanoco quantum dots has the
potential to give surgeons a much greater window than currently available for
the removal of cancer cells. 
 
"We look forward to continuing this research with the ultimate objective of
our technology becoming part of a commercially available bio-imaging product.
This bio-imaging research highlights the versatility of our core cadmium-free
quantum dot technology and its multiple potential commercial applications of
which the display sector is our lead focus." 
 
For further information please contact: 
 
 Nanoco                                      + 44 (0) 161 603 7900  
 Michael Edelman, Chief Executive Officer                           
 Colin White, Chief Financial Officer                               
 Canaccord Genuity - Nomad and Joint Broker  +44 (0) 20 7523 8000   
 Simon Bridges                                                      
 Cameron Duncan                                                     
 Liberum Capital - Joint Broker              +44 (0) 20 3100 2000   
 Simon Atkinson                                                     
 Richard Bootle                                                     
 Buchanan                                    + 44 (0) 20 7466 5000  
 Mark Court / Fiona Henson / Sophie Cowles                          
 
 
Mark Court / Fiona Henson / Sophie Cowles 
 
Notes for editors: 
 
About Nanoco Group plc 
 
Nanoco is a world leader in the development and production of cadmium-free
quantum dots and other nano-materials for use in multiple applications
including LCD displays, lighting, solar cells and bio-imaging. In the display
market, it has an exclusive manufacturing and marketing licensing agreement
with The Dow Chemical Company. 
 
Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has
production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based
in Concord, MA. Nanoco also has business development offices in Japan, Korea
and Taiwan. Its technology is protected worldwide by a large and growing
patent estate. 
 
Nanoco began trading on the AIM market of the London Stock Exchange in May
2009 under the ticker symbol NANO. For further information please visit:
www.nanocogroup.com. 
 
This information is provided by RNS
The company news service from the London Stock Exchange